Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × enzalutamide × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 26 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Neoplasms 3 Neoplasm Metastasis 3 Prostatic Neoplasms, Castration-Resistant 2 Prostate Cancer Metastatic 2 Metastatic Hormone Sensitive Prostate Cancer 2 mCRPC 1 Recurrence 1 Prostatic Diseases 1 Patient Preference 1 Metastatic Castration-resistent Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-resistant Prostate Cancer 1 Metastatic Castration-Resistant Prostate Cancer 1 MCRPC 1 Genital Diseases, Male 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Dexamethasone 23 Rituximab 15 Gemcitabine 11 Cisplatin 11 pomalidomide 10 Paclitaxel 10 Lenalidomide 9 Bortezomib 9 Carboplatin 8 Cyclophosphamide 7 carfilzomib 6 Drug Therapy 5 Cytarabine 5 selinexor 4 ibrutinib 4 daratumumab 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 ofatumumab 2 galiximab 2 eculizumab 2 durvalumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06551324 2026-03-04

MEVPRO-1

Pfizer

Phase 3 Recruiting

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡